Patent · US Active

Preparation of and formulation comprising a MEK inhibitor

US9562016B2 · kind B2 · utility

4Cited by

4References

16Claims

0Family size

Assignees

Array BioPharma, Inc. · US
Novartis AG · CH

Inventors

Christoph Max Krell · Basel, CH
Marian Misun · Basel, CH
Daniel Andreas Niederer · Basel, CH
Werner Heinz Pachinger · Basel, CH
Marie-Christine Wolf · Basel, CH
Daniel Zimmermann · Basel, CH
Weidong Liu · Superior, US
Peter J. Stengel · Boulder, US
Paul Nichols · Firestone, US

Key dates

Filing date	Dec 18, 2015
Grant date	Feb 7, 2017
Priority date	—
Expiry date	Dec 18, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.